Why It Matters

The House Science, Space, and Technology Subcommittee on Investigations and Oversight will convene on September 16 to examine the intersection of biotechnology innovation and national security.

The timing reflects broader pressure. The House Science, Space & Technology Committee has been actively seeking information from federal agencies about gaps and vulnerabilities in biotechnology oversight, asking whether they have implemented recommendations from the National Security Commission on Emerging Biotechnology. The committee has also asked agencies to identify what additional authorities, resources, or statutory changes may be needed to protect U.S. biotech advantage while securing the field against biosecurity threats.

The Hearing

The hearing, titled "Balancing Biotechnology Innovation and Biosecurity: Securing U.S. Leadership In A Global Race," will be held on September 16. Dr. Rich McCormick serves as Chair of the Science, Space, and Technology Subcommittee on Investigations and Oversight, and Emilia Sykes serves as Ranking Member of the Science, Space, and Technology Subcommittee on Investigations and Oversight.

Context

Lawmakers have identified specific policy concerns. Members of the House BIOTech caucus flagged intellectual property protection and AI-enabled gene synthesis as priority issues. However, they stated they will not push new legislation forward before the end of the year.

At the industry level, significant lobbying activity reflects the sector's stakes. The Biotechnology Innovation Organization (BIO) reported $2.36 million in second quarter 2026 lobbying expenditures, with disclosures covering appropriations, antitrust legislation, and foreign investment scrutiny. Applied Materials Inc. spent $60,000 in the same period on semiconductor and manufacturing technology issues, including export controls.

On the legislative front, a bipartisan Biosecurity Modernization and Innovation Act of 2026 has emerged, endorsed by the National Security Threat Initiative (NTI). According to Sen. Tom Cotton, the bill represents an important first step toward comprehensive biosecurity and biosafety frameworks. Cotton stated that the legislation will encourage American innovation to flourish while protecting biotechnology breakthroughs in medicine and agriculture.

He noted that access to genetic material enables scientists to study diseases and develop lifesaving medicine, but without safety standards, genetic material could be misused to create bioweapons. Cotton argued that the bipartisan measure will enhance biosecurity efforts and reduce the risk of genetic material being used to cause harm by ensuring companies selling genetic products meet safety standards.

Separately, the BIOSECURE Act aims to prevent U.S. taxpayer dollars from flowing to foreign adversary biotech companies by prohibiting government procurement of products to which specific Chinese contract research organizations or contract development and manufacturing organizations have contributed. The law also encourages the onshoring of manufacturing.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article